Archive | September, 2009
Agendia Secures 23 Million E Series Financing
A world leader in molecular cancer diagnostics, Agendia has successfully closed their E series financing and has raised US$ 23 million as an investment. The Dutch molecular cancer diagnostics company further announced that the financing round was led by an undisclosed family investment firm who has contributed around more than half of their E Series [...]
Continue reading...Vaccine Proved Effective Against HIV (VXGN, OTC:VXGN)
24 September 2009 – 1:53 pm PST
Comments Off
HIV has been one of the most devastating viruses to ever hit mankind. So far there have been no vaccines developed that have had much if any success rate in preventing the disease and its fatal consequence. However that has all changed due to a study conducted in Thailand. Preliminary results show that a combination [...]
Continue reading...Nycomed eyes Solvay SA’s drug operations
24 September 2009 – 1:41 pm PST
Comments Off
In an attempt to takeover the European junk bonds after the financial crisis, Nycomed, one of the private equity-owned Swiss drugmaker has made a 4.5 billion Euros bid to purchase Solvay SA’s drug operations. The Zurich based company said that it this bid and takeover is finalized it will help them to reach their annual [...]
Continue reading...FDA approves Auxilium’s Xiaflex therapy
24 September 2009 – 1:37 pm PST
Comments Off
FDA advisory panel has backed and given a green signal to Auxilium Pharmaceutical’s experimental Xiaflex therapy which cures Dupuytren’s contracture. The FDA panel has stated that the Xiaflex therapy is absolutely effective and safe and a better alternative to surgery as a treatment for a condition that affects the connective tissues in the hand. With [...]
Continue reading...Inc. Magazine Announces The Top 100 Fastest Growing Companies
21 September 2009 – 11:28 am PST
Comments Off
The companies must be privately held and are judged on the increase of their revenues for four years. Whether the company is profitable, has increased profits, or has had a decline in income isn’t taken into consideration. While the companies are announced in 2009, the performance is 2005 through 2008. The company must be based [...]
Continue reading...Swine Flu N1H1, What Makes This Flu Scary (SVA, GLID, GSK, NVS)
16 September 2009 – 9:00 am PST
Comments Off
Swine Flu, officially known as N1H1 influenza , is having a far reaching effect on every one of us. The virus was first tracked in a small town in Mexico in May of 2009 and has spread to nearly every part of the world. The World Health Organization considers it a phase 6 pandemic. Individual [...]
Continue reading...BioElectronics Making BIG News This Week (BIEL)
15 September 2009 – 11:33 am PST
Comments Off
The BioElectronics Corp (Public, OTC BIEL) has been making news this week, with the announcement of their schedule for filing with the U.S. Food and Drug Administration for 510 (K) pre-marketing clearance. It has also been announced the biotech company is a runner up in the 2009 Technology Innovation winners for their wearable drug-free patch [...]
Continue reading...ALR Technologies Patent Approved for Nebulizer Compressors (OTC:ALRT)
15 September 2009 – 8:27 am PST
Comments Off
The nebulizer compressors that ALR Technologies (Public, OTC: ALRT) had applied for a patent application has been approved by the U.S. Patent Office. This is a patent to protect the Health-E-Connect management communications system. The Health-E-Connect system will help to remotely monitor patients suffering from chronic asthma, COPD and cystic fibrosis using nebulizer compressors.
Continue reading...Lenders Lower Spending Limits on Select Credit Card Holders
14 September 2009 – 4:33 pm PST
Comments Off
FICO announced last week that while the lowering of spending limits by lenders may dramatically affect some card holders, the effort had little impact overall on credit scores. Nearly $100 million dollars of bad credit card debt is projected to be charged off in 2009 as consumers default in record numbers. Lenders are countering by [...]
Continue reading...Discovery Labs – FDA meet for Surfaxin approval (DSCO)
14 September 2009 – 9:56 am PST
Comments Off
After a sit-down plan with the FDA regulators over the possibility of a limited trial, shares of Discovery Laboratories suddenly saw an upwards trend. This meeting will help Discovery Laboratories to get more information and data to overcome the outstanding primary concerns related to its respiratory drug Surfaxin.
Continue reading...
25 September 2009 – 11:24 am PST
Comments Off